Selecta Biosciences (NASDAQ:SELB) announced its quarterly earnings data on Friday. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.10, MarketWatch Earnings reports. The business had revenue of $0.90 million for the quarter.

SELB opened at $2.17 on Friday. Selecta Biosciences has a fifty-two week low of $1.41 and a fifty-two week high of $16.55. The stock has a market cap of $48.76 million, a PE ratio of -0.68 and a beta of 1.55.

In other news, Director Amir Nashat purchased 1,166,666 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was bought at an average cost of $1.50 per share, with a total value of $1,749,999.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 25.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Selecta Biosciences by 87.6% during the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock worth $34,000 after purchasing an additional 5,911 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Selecta Biosciences by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock valued at $10,197,000 after acquiring an additional 6,859 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Selecta Biosciences by 50.3% in the 4th quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock valued at $63,000 after acquiring an additional 7,965 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Selecta Biosciences by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after acquiring an additional 8,500 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Selecta Biosciences in the 3rd quarter valued at approximately $196,000. 46.73% of the stock is owned by institutional investors.

SELB has been the subject of a number of research reports. Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 10th. Needham & Company LLC cut their price target on Selecta Biosciences to $12.00 and set a “buy” rating for the company in a research note on Monday, January 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $7.00 price target on shares of Selecta Biosciences in a research note on Friday. Mizuho cut their price target on Selecta Biosciences to $4.00 and set a “buy” rating for the company in a research note on Monday, February 4th. Finally, ValuEngine downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $15.46.

COPYRIGHT VIOLATION NOTICE: “Selecta Biosciences (SELB) Announces Earnings Results” was first published by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.mareainformativa.com/news/2019/03/17/selecta-biosciences-selb-announces-earnings-results.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Featured Story: How To Calculate Debt-to-Equity Ratio

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.